Healthcare / Drug Manufacturers - Specialty & GenericKuala Lumpur
$1.22
+0.01 (+0.83%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $49.5M · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
12.2x
↓EV/EBITDA
7.4x
↓ROE
11.5%
↑Gross Margin
39.0%
↓Debt/Equity
0.65
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.2%
FCF CAGR
—
FCF margin
7.9%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $931.7M · net income $87.5M · FCF $73.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $931.7M | $931.7M | $813.7M | $704.7M | $696.7M |
| Net Income | $87.5M | $87.5M | $62.6M | $52.6M | $70.1M |
| EBITDA | $185.3M | $185.3M | $152.0M | $124.0M | $130.1M |
| EPS | 0.09 | 0.09 | 0.07 | 0.05 | 0.07 |
| Gross Margin | 39.0% | 39.0% | 37.1% | 38.1% | 40.2% |
| Operating Margin | 14.4% | 14.4% | 12.4% | 11.8% | 13.3% |
| Net Margin | 9.4% | 9.4% | 7.7% | 7.5% | 10.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.65 | 0.65 | 0.73 | 0.80 | 0.66 |
| Current Ratio | 2.62 | 2.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $73.8M | $73.8M | $49.5M | $9.2M | $-756000.00 |
| Returns | |||||
| ROE | 11.5% | 11.5% | 8.8% | 7.7% | 10.7% |
| Valuation | |||||
| P/E | 12.20 | 12.20 | 19.20 | 23.32 | 22.06 |
| EV/EBITDA | 7.42 | 7.42 | 9.57 | 12.14 | 13.98 |
| P/B | 1.55 | 1.55 | 1.70 | 1.79 | 2.36 |
| Growth & Yield | |||||
| Revenue Growth | 14.5% | 14.5% | 15.5% | 1.1% | — |
| EPS Growth | 39.6% | 39.6% | 18.6% | -25.7% | — |
| Dividend Yield | 3.7% | 3.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.0%
EPS terminal req.
$0.11
Spread vs growth
33.6%
5Y implied EPS CAGR
7.6%
EPS terminal req.
$0.13
Spread vs growth
32.1%
10Y implied EPS CAGR
8.8%
EPS terminal req.
$0.21
Spread vs growth
30.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.4%
Start / end P/E
20.0x → 13.4x
EPS bridge
0.07 → 0.09
Residual
-13.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.